Notes And Other Explanatory Information [Abstract]
| Concept |
2024-01-01 to 2024-12-31 |
|---|---|
| Notes and other explanatory information [abstract] | |
| Disclosure of accounting judgements and estimates [text block] |
3. Significant accounting estimates and assumptions
|
| Disclosure of accrued expenses and other liabilities [text block] |
22
|
| Disclosure of authorisation of financial statements [text block] |
The annual separate financial statement for 2024 for PCI Biotech Holding ASA (the Company) and the
|
| Disclosure of basis of consolidation [text block] |
2.2 Basis of consolidation
|
| Disclosure of basis of preparation of financial statements [text block] |
2. Significant accounting policies
|
| Disclosure of changes in accounting policies, accounting estimates and errors [text block] |
2.4 Changes in accounting policies and disclosures
|
| Disclosure of credit risk [text block] |
Credit risk
|
| Disclosure of debt instruments [text block] |
21
|
| Disclosure of derivative financial instruments [text block] |
8
|
| Disclosure of earnings per share [text block] |
13
|
| Disclosure of effect of changes in foreign exchange rates [text block] |
Foreign currency risk
|
| Disclosure of entity's operating segments [text block] |
6
|
| Disclosure of events after reporting period [text block] |
A total of 75,000 share options were allotted to Morten Luhr connected to his promotion to Chief
|
| Disclosure of financial risk management [text block] |
16
|
| Disclosure of going concern [text block] |
25
|
| Disclosure of impairment of assets [text block] |
14
|
| Disclosure of information about key management personnel [text block] |
20
|
| Disclosure of interest income (expense) [text block] |
11
|
| Disclosure of liquidity risk [text block] |
Liquidity risk
|
| Disclosure of market risk [text block] |
(II) Classes of financial risk
|
| Disclosure of other assets [text block] |
18
|
| Disclosure of other liabilities [text block] |
Group
|
| Disclosure of other operating income (expense) [text block] |
5
|
| Disclosure of research and development expense [text block] |
7
|
| Disclosure of restricted cash and cash equivalents [text block] |
19
|
| Disclosure of tax receivables and payables [text block] |
12
|
| Disclosure of trade and other receivables [text block] |
17
|